Heyu Biological Technology Corporation
HYBT · OTC
9/30/2025 | 6/30/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -3.11 | 0.00 | -0.37 | 0.00 |
| FCF Yield | -0.35% | -0.25% | 6.33% | -9.86% |
| EV / EBITDA | 614.94 | 288.25 | -767.01 | -3,088.75 |
| Quality | ||||
| ROIC | 0.54% | 0.93% | -0.32% | -0.09% |
| Gross Margin | 17.49% | 15.96% | 71.41% | 6.11% |
| Cash Conversion Ratio | -0.48 | -0.46 | 8.28 | -46.22 |
| Growth | ||||
| Revenue 3-Year CAGR | 397.57% | 347.89% | 230.38% | 384.94% |
| Free Cash Flow Growth | -40.01% | 0.00% | 164.16% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 27.99 | 12.83 | -32.54 | -123.79 |
| Interest Coverage | -13.14 | 553.49 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 72.62 | 110.01 | 0.00 | 0.42 |
| Cash Conversion Cycle | 41.42 | 8.47 | 18.54 | 230.46 |